Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na ïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Condition:   Leukemia Interventions:   Drug: Pirtobrutinib;   Drug: Obinutuzumab;   Drug: Venetoclax;   Drug: Valacyclovir;   Drug: Allopurinol Sponsors:   M.D. Anderson Cancer Center;   Loxo Oncology, Inc.;   The Leukemia and Lymphoma Society Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials